Elevate your local knowledge
Sign up for the iNFOnews newsletter today!
LONDON – The board of pharmaceutical company AstraZeneca has rejected drug maker Pfizer’s sweetened takeover offer.
The board says in a statement Friday that the terms are inadequate and substantially undervalue AstraZeneca. It says the board did not hesitate in rejecting the proposal.
THIS IS A BREAKING NEWS UPDATE. Check back soon for further information. AP’s earlier story is below.
___
Drug maker Pfizer sweetened its takeover offer for U.K.-based AstraZeneca on Friday and outlined measures it hopes will ease British government concerns over the deal.
The Viagra maker said it is offering 50 pounds ($84) a share in cash and stock, a 7.3 increase on the previous bid. The offer values AstraZeneca at $106 billion.
“There is a highly compelling strategic, business and financial rationale for combining our businesses, with significant benefits for shareholders and stakeholders of both companies,” Pfizer CEO Ian Read said in a statement announcing the offer.
AstraZeneca, which had shot down earlier takeover attempts, replied in a statement that its board would meet to discuss the latest offer.
Pfizer also sent a letter to Prime Minister David Cameron, promising to keep the country’s corporate and tax residence in England and saying the “golden triangle of Oxford, Cambridge and London would represent a vital component” of the deal.
Critics fear the takeover could mean big job losses, and the potential loss of stature in the science sector in Britain has become a political issue.
“This does look a little bit like a transaction which has tax planning as a rationale,” the opposition Labour Party’s shadow business secretary, Chuka Umunna, told the BBC.
Pfizer Inc. is the world’s second-biggest drugmaker by revenue — while AstraZeneca PLC ranks eighth. AstraZeneca was created in 1999 through the merger of Sweden’s Astra and Britain’s Zeneca.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.